Braxia Scientific team-led guidelines into clinical uses of ketamine and esketamine published in prestigious American Journal of Psychiatry Its CEO Roger McIntyre and medical director Joshua Rosenblat led a team of experts to develop the International Expert Opinion and Implementation Guidance for the clinical use of rapid-acting ketamine and esketamine for treatment-resistant depression Esketamine therapy received FDA approval with "breakthrough status" in 2019 Braxia Scientific Corp (CSE:BRAX) (OTCMKTS:BRAXF) (FRA:496) CEO Roger McIntyre saw his research into the clinical uses of ketamine and esketamine published in the prestigious American Journal of Psychiatry. McIntyre and Braxia’s medical director Joshua Rosenblat led a team of 26 experts to develop the International Expert Opinion and Implementation Guidance (Guidelines) for the clinical use of rapid-acting Ketamine and Esketamine for treatment-resistant depression, according to Braxia.